Cost-effectiveness of sotorasib as a second-line treatment for non-small cell lung cancer with KRASG12C mutation in China and the United States
Article in Frontiers in Pharmacology (June 2024)
The most recent citing publications are shown below. View all 7 publications that cite this research output on Dimensions.
Comparison of Efficacy, safety, and cost-effectiveness of pembrolizumab versus chemotherapy for patients with advanced non-small cell lung cancer: a real-world study
Preprint in Research Square (April 2024)
Cost-Effectiveness of Treatment Optimisation with Biomarkers for Immunotherapy in Solid Tumours: A Systematic Review
Article in Cancers (February 2024)